ACADIA HEALTHCARE COMPANY, INC.00404A109US00404A109705/06/2026Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER45200000FOR4520000FOR1 ADAPTHEALTH CORP.00653Q102US00653Q102206/18/2026Say-on-Pay - Non-binding advisory vote to approve the compensation paid to AdaptHealth's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER95202380FOR9520238FOR1 ALECTOR, INC.014442107US014442107206/17/2026Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER10551920FOR1055192FOR1 ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/20/2026To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER679350FOR67935FOR1 ANNEXON, INC.03589W102US03589W102706/11/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER5839130FOR583913FOR1 ARROWHEAD PHARMACEUTICALS, INC.04280A100US04280A100703/19/2026Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER15915590FOR1591559FOR1 ARS PHARMACEUTICALS, INC.82835W108US82835W108006/24/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER66129860FOR6612986FOR1 ARS PHARMACEUTICALS, INC.82835W108US82835W108006/24/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER661298601 YEAR6612986FOR1 AZENTA, INC.114340102US114340102401/28/2026To approve by a non-binding advisory vote the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER001 BELLRING BRANDS, INC.07831C103US07831C103601/28/2026To consider and vote, on an advisory basis, for the adoption of a resolution approving the compensation of our named executive officers, as such compensation is described under the "Compensation Discussion and Analysis" and "Executive Compensation" sections of this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER001 BIO-RAD LABORATORIES, INC.090572207US090572207204/21/2026Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER170602.057390FOR170602.05739FOR1 BIO-TECHNE CORP09073M104US09073M104510/30/2025Approve, on an advisory basis, the compensation of our executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER230410ABSTAIN23041AGAINST1 BIOCRYST PHARMACEUTICALS, INC.09058V103US09058V103506/11/2026To hold a non-binding, advisory vote regarding executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER108626300FOR10862630FOR1 BIOLIFE SOLUTIONS, INC.09062W204US09062W204408/20/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER001 BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER8515560FOR851556FOR1 BROOKDALE SENIOR LIVING INC.112463104US112463104507/11/2025Advisory approval of named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER153622640FOR15362264FOR1 BROOKDALE SENIOR LIVING INC.112463104US112463104506/22/2026Advisory approval of named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER116370320FOR11637032FOR1 CARDINAL HEALTH, INC.14149Y108US14149Y108211/05/2025To approve, on a non-binding advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER1200ABSTAIN120AGAINST1 CAREDX, INC.14167L103US14167L103506/11/2026Approval, on an advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER21910000FOR2191000FOR1 CAREDX, INC.14167L103US14167L103506/11/2026To vote, on an advisory basis, the frequency of advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER219100001 YEAR2191000FOR1 CELCUITY INC.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER9587240FOR958724FOR1 CENTENE CORPORATION15135B101US15135B101705/12/2026ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER51747100FOR5174710FOR1 CERTARA, INC.15687V109US15687V109805/14/2026A non-binding advisory vote to approve the compensation of our named executive officers for the most recently completed fiscal year.SECTION 14A SAY-ON-PAY VOTESISSUER35354942273111FOR3535494FOR1 COGENT BIOSCIENCES, INC.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER40946590FOR4094659FOR1 COMPASS THERAPEUTICS, INC.20454B104US20454B104406/10/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER36060000FOR3606000FOR1 COMPASS THERAPEUTICS, INC.20454B104US20454B104406/10/2026To approve, on a non-binding, advisory basis, the holding of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER360600001 YEAR3606000FOR1 CULLINAN THERAPEUTICS, INC.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER3861690FOR386169FOR1 DIANTHUS THERAPEUTICS, INC.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER001 DISC MEDICINE, INC.254604101US254604101106/18/2026To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4797500FOR479750FOR1 EDWARDS LIFESCIENCES CORPORATION28176E108US28176E108205/07/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER137020FOR13702FOR1 EMBECTA CORP29082K105US29082K105102/11/2026Advisory vote to approve named executive officer compensationSECTION 14A SAY-ON-PAY VOTESISSUER27656110FOR2765611FOR1 ENHABIT, INC.29332G102US29332G102205/12/2026Approval, on a non-binding, advisory basis, certain compensation that may be paid or become payable to Enhabit's named executive officers that is based on or otherwise relates to the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER47477460FOR4747746FOR1 ENVISTA HOLDINGS CORPORATION29415F104US29415F104905/19/2026To approve on an advisory basis Envista's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER22101000FOR2210100FOR1 ENVISTA HOLDINGS CORPORATION29415F104US29415F104905/19/2026To hold an advisory vote relating to the frequency of future stockholder(s)advisory votes on Envista's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER221010001 YEAR2210100FOR1 FOGHORN THERAPEUTICS INC.344174107US344174107706/24/2026To approve, on an advisory basis, the compensation of Foghorn's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER43943670FOR4394367FOR1 FOGHORN THERAPEUTICS INC.344174107US344174107706/24/2026To approve, on an advisory basis, the frequency of future advisory votes on the compensation of Foghorn's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER439436701 YEAR4394367FOR1 HAEMONETICS CORPORATION405024100US405024100307/24/2025To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER001 HUMANA INC.444859102US444859102804/16/2026Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER9170FOR917FOR1 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;SECTION 14A SAY-ON-PAY VOTESISSUER16844010FOR1684401FOR1 INDIVIOR PHARMACEUTICALS, INC.45579U109US45579U109705/13/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER30977900FOR3097790FOR1 INDIVIOR PHARMACEUTICALS, INC.45579U109US45579U109705/13/2026To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER309779001 YEAR3097790FOR1 INSPIRE MEDICAL SYSTEMS, INC.457730109US457730109004/30/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER23762380FOR2376238FOR1 INSPIRE MEDICAL SYSTEMS, INC.457730109US457730109004/30/2026Approval, on an advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER237623801 YEAR2376238FOR1 IONIS PHARMACEUTICALS, INC.462222100US462222100406/04/2026To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER19796690FOR1979669FOR1 KENVUE INC.49177J102US49177J102501/29/2026To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Kenvue Inc.'s named executive officers that is based on or otherwise relates to the transactions contemplated by the Merger Agreement.SECTION 14A SAY-ON-PAY VOTESISSUER586290ABSTAIN58629AGAINST1 KYMERA THERAPEUTICS, INC.501575104US501575104406/24/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER5611700FOR561170FOR1 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The approval, on an advisory basis, of the compensation paid to our named executive officers (commonly referred to as ''say on pay'').SECTION 14A SAY-ON-PAY VOTESISSUER8279990FOR827999FOR1 LANTHEUS HOLDINGS, INC.516544103US516544103204/30/2026The approval, on an advisory basis, of the frequency of holding future ''say on pay'' votes.SECTION 14A SAY-ON-PAY VOTESISSUER82799901 YEAR827999FOR1 LARIMAR THERAPEUTICS, INC.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER356069740FOR35606974FOR1 LARIMAR THERAPEUTICS, INC.517125100US517125100305/19/2026Approval, on an Advisory Basis, of the Preferred Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER3560697401 YEAR35606974FOR1 LINDE PLCG54950103IE000S9YS76207/29/2025To approve, on an advisory and non-binding basis, the compensation of Linde plc's Named Executive Officers, as disclosed in the 2025 Proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER130ABSTAIN13AGAINST1 LINDE PLCG54950103IE000S9YS76207/29/2025To recommend, on an advisory and non-binding basis, the frequency of holding future advisory shareholder votes on the compensation of Linde plc's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER130ABSTAIN13AGAINST1 MAXIMUS, INC.577933104US577933104103/10/2026Advisory vote to approve the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER73130ABSTAIN7313AGAINST1 MERUS N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTESISSUER30469160FOR3046916FOR1 MONOPAR THERAPEUTICS, INC.61023L207US61023L207906/22/2026To approve the compensation of our named executive officers on an advisory, non-binding basis.SECTION 14A SAY-ON-PAY VOTESISSUER3237450FOR323745FOR1 MYRIAD GENETICS, INC.62855J104US62855J104306/04/2026To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER5050FOR505FOR1 NEUROCRINE BIOSCIENCES, INC.64125C109US64125C109905/27/2026Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER2978190FOR297819FOR1 NEWAMSTERDAM PHARMA COMPANY N.V.N62509109NL00150012L706/02/2026Non-binding, advisory vote to approve the 2025 compensation of named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER42647890FOR4264789FOR1 NUVALENT, INC.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER172484500FOR17248450FOR1 PMV PHARMACEUTICALS INC.69353Y103US69353Y103806/04/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER87900FOR8790FOR1 PRAXIS PRECISION MEDICINES, INC.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER5547220FOR554722FOR1 REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER225610840892FOR2256108FOR1 SAVARA INC.805111101US805111101606/04/2026To approve, on an advisory basis, the compensation of our named executives.SECTION 14A SAY-ON-PAY VOTESISSUER135690000FOR13569000FOR1 STAAR SURGICAL COMPANY852312305US852312305201/06/2026A proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to STAAR's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement.SECTION 14A SAY-ON-PAY VOTESISSUER1000220ABSTAIN100022AGAINST1 STERIS PLCG8473T100IE00BFY8C75407/31/2025To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed pursuant to the disclosure rules of the U.S. Securities and Exchange Commission, including the compensation discussion and analysis and the tabular and narrative disclosure contained in the Company's proxy statement dated June 12, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER3500ABSTAIN350AGAINST1 STOKE THERAPEUTICS, INC.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER18235000FOR1823500FOR1 STRUCTURE THERAPEUTICS, INC.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER8740000FOR874000FOR1 SYNDAX PHARMACEUTICALS, INC87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER27017490FOR2701749FOR1 TANGO THERAPEUTICS, INC.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER41468130FOR4146813FOR1 TAYSHA GENE THERAPIES, INC.877619106US877619106106/01/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER27221650FOR2722165FOR1 TAYSHA GENE THERAPIES, INC.877619106US877619106106/01/2026To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER272216501 YEAR2722165FOR1 THE ONCOLOGY INSTITUTE, INC.68236X100US68236X100006/17/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER327498546FOR3274985FOR1 THE ONCOLOGY INSTITUTE, INC.68236X100US68236X100006/17/2026Approval, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3274985461 YEAR3274985FOR1 UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER4570000FOR457000FOR1 VAREX IMAGING CORPORATION92214X106US92214X106302/12/2026To approve, on an advisory basis, our executive compensation as described in the accompanying Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1458770ABSTAIN145877AGAINST1 VERA THERAPEUTICS, INC.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER20557970FOR2055797FOR1 VERACYTE, INC.92337F107US92337F107506/10/2026The approval, on a non-binding advisory basis, of the compensation of our named executive officers, as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER6652440FOR665244FOR1 VIATRIS INC.92556V106US92556V106112/05/2025Approval of, on a non-binding advisory basis, the 2024 compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER2339577257907FOR23395772FOR1 VIATRIS INC.92556V106US92556V106105/15/2026Approval of, on a non-binding advisory basis, the 2025 compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER199434690FOR19943469FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER16156960FOR1615696FOR1 XENON PHARMACEUTICALS INC98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER161569601 YEAR1615696FOR1